Home Companies Catalysts Deep Dives
Farxiga dapagliflozin APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Launch2014-01-08
US LOE2026-12-12
Peak Sales Est$7000M
Formulations[{"id":"farxiga-oral","doses":"5mg, 10mg","route":"PO","device":"Tablet","setting":"PATIENT_SELF","f
Companies
AZN (ORIGINATOR)100%
Mechanism: SGLT2 inhibitor
Expert: Sodium-glucose co-transporter 2 inhibitor that reduces glucose reabsorption in proximal tubule; cardioprotective effects via hemodynamic, metabolic, and anti-inflammatory mechanisms.
Everyday: Helps the body remove excess sugar through urine, also protects the heart and kidneys.
Targets: ["SGLT2"]
Revenue History
PeriodRevenue ($M)
2023$5,962M
2024$6,762M
Q1 2025$1,820M
Q2 2025$1,950M
Programs (3)
IndicationStageKey StudyRegional Status
HFAPPROVEDDAPA-HF[{"stage":"APPROVED","region":"US","approval_date":"2020-05-05"},{"stage":"APPRO
CKDAPPROVEDDAPA-CKD[{"stage":"APPROVED","region":"US","approval_date":"2021-04-30"},{"stage":"APPRO
T2DAPPROVEDDECLARE-TIMI 58[{"stage":"APPROVED","region":"US","approval_date":"2014-01-08"},{"stage":"APPRO
Notes
SGLT2 inhibitor. Diabetes, HF, CKD.
Data from Supabase · Updated 2026-03-24